Different effect of the pure Na+ channel-blocker pilsicainide on the ST-segment response in the right precordial leads in patients with normal left ventricular function

Circulation Journal

Volumn 71, Issue 1, 2007, Pages 57-62

  Ueyama, Takeshi ^a   Shimizu, Akihiko ^a   Yamagata, Toshihiko ^b   Esato, Masahiro ^a   Ohmura, Masato ^a   Yoshiga, Yasuhiro ^a   Kanemoto, Masashi ^a   Kametani, Ryousuke ^a   Sawa, Akira ^a   Suzuki, Shinsuke ^a   Sugi, Naoki ^a   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yamaguchi Grand Medical Center   (Japan)

Author keywords

Brugada syndrome; Brugada type ECG; Drug challenge test; Pilsicainide; ST segment

Indexed keywords

PILSICAINIDE; SODIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; BRUGADA SYNDROME; COMPUTER AIDED DESIGN; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HUMAN EXPERIMENT; MALE; PROVOCATION TEST; ST SEGMENT; WAVEFORM;

ADULT; AGED; ALGORITHMS; BRUGADA SYNDROME; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM CHANNEL BLOCKERS; VENTRICULAR FUNCTION, LEFT;

EID: 33846032348     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.57     Document Type: Article

References (28)

1. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27: 1061-1070.
2. Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997; 8: 325-331.
3. Morita H, Morita ST, Nagase S, Banba K, Nishii N, Tani Y, et al. Ventricular arrhythmia induced by sodium channel blocker in pa-tients with Brugada syndrome. J Am Coll Cardiol 2003; 42: 1624-1631.
4. Wilde AAM, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al for the Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology. Proposed diagnostic criteria for the Brugada syndrome: Consensus report. Circulation 2002; 106: 2514-2519.
5. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: Report of the second consensus conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659-670.
6. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510-515.
7. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Brignole M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation 2000; 102: 2509-2515.
8. Beldner S, Lin D, Marchlinski FE. Flecainide and propafenone induced ST-segment elevation in patients with atrial fibrillation: Clue to specificity of Brugada-type electrocardiographic changes. Am J Cardiol 2004; 94: 1184-1185.
9. Rolf S, Bruns HJ, Wichter T, Kirchhof P, Ribbing M, Wasmer K, et al. The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol. Eur Heart J 2003; 24: 1104-1112.
10. Hong K, Brugada J, Oliva A, Berruezo-Sanchez A, Potenza D, Pollevick GD, et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004; 110: 3023-3027.
11. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851.
12. Kodama I, Ogawa S, Inoue H, Kasanuki H, Kato T, Mitamura H, et al. Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. Jpn Circ J 1999; 63: 1-12.
13. Antzelevitch C. The Brugada syndrome: Diagnostic criteria and cellular mechanisms. Eur Heart J 2001; 22: 356-363.
14. Goethals P, Debmyne P, Saffarian M. Drug-induced Brugada syndrome. Acta Cardiol 1998; 53: 157-160.
15. Matana A, Goldner V, Stanic K, Mavric Z, Zaputovic L, Matana Z. Unmasking effect of propafenone on the concealed form of the Brugada phenomenon. Pacing Clin Electrophysiol 2000; 23: 416-418.
16. Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T, et al. Brugada syndrome and supraventricular tachyarrhythmias: A novel association? J Cardiovasc Electrophysiol 2001; 12: 680-685.
17. Morita H, Kusano KF, Nagase S, Fujimoto Y, Hisamatsu K, Fujio H, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40: 1437-1444.
18. Bordachar P, Reuter S, Garrigue S, Caï X, Hocini M, Jaïs P, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in brugada syndrome. Eur Heart J 2004; 25: 879-884.
19. Hattori Y, Hidaka T, Aisaka K, Satoh F, Ishihara T. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles. J Cardiovasc Pharmacol 1988; 11: 407-412.
20. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 1998; 9: 513-516.
21. Antzelevitch C, Brugada P, Brugada J, Brugada R, Towbin JA, Nademanee K. Brugada syndrome: 1992-2002: A historical perspective. J Am Coll Cardiol 2003; 41: 1665-1671.
22. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong P, Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 2001; 22: 2290-2296.
23. Hisamatsu K, Morita H, Kusano KF, Takenaka S, Nagase S, Nakamura K, et al. Evaluation of the usefulness of recording the ECG in the 3rd intercostal space and prevalence of Brugada-type ECG in accordance with recently established electrocardiographic criteria. Circ J 2004; 68: 135-138.
24. Nakazawa K, Sakurai T, Takagi A, Kishi R, Osada K, Miyazu O, et al. Clinical significance of electrocardiography recordings from a higher intercostal space for detection of the Brugada sign. Circ J 2004; 68: 1018-1022.
25. Meregalli PG, Wilde AAM, Tan HL. Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more? Cardiovasc Res 2005; 67: 367-278.
26. Priori SG, Napolitano C. Management of patients with Brugada syndrome should not be based on programmed electrical stimulation. Circulation 2005; 112: 285-291.
27. Peters S, Trummel M, Denecke S, Koehler B. Results of ajmaline testing in patients with arrhythmogenic right ventricular dysplagia-cardiomyopathy. Int J Cardiol 2004; 95: 207-210.
28. Goda A, Yamashita T, Kato T, Koike A, Sagara K, Kirigaya H, et al. Pilsicainide-induced coronary vasospasm in a patient with Brugada-type electrocardiogram: A case report. Cire J 2005; 69: 858-860.